UroGen Pharma Ltd. (URGN): Gross Profit
$97.34M
Year ended 2025-12-31
$171.46M
Trailing 12 months to 2026-06-30
+19.7%
3-year compound annual growth
+55.3%
5-year compound annual growth
| Period ended | Gross Profit | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $97.34M | +19.4% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $81.52M | +11.1% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $73.35M | +29.4% | 2025-03-10, From 2023-01-01 |
| 2022-12-31 | $56.70M | +32.2% | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | $42.88M | +297.5% | 2023-03-24, From 2021-01-01 |
| 2020-12-31 | $10.79M | n/m | 2022-03-21, From 2020-01-01 |
| 2019-12-31 | $18.0K | n/m | 2021-03-18, From 2019-01-01 |
| 2018-12-31 | -$675.0K | n/m | 2020-03-02, From 2018-01-01 |
| 2017-12-31 | $7.56M | -56.8% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $17.50M | n/a | 2019-02-28, From 2016-01-01 |
Gross Profit at similar companies
| Company | Year ended | Gross Profit | Change YoY |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $97.34M | +19.4% |
| Gyre Therapeutics, Inc. (GYRE) | 2024-12-31 | $101.87M | -6.4% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $64.87M | -39.6% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $40.30M | -3.7% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $42.54M | -5.2% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $75.56M | +16.4% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $75.02M | +87.2% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $42.74M | +82.6% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $113.56M | +7.5% |
Compare URGN, GYRE, SIGA, LFCR side by side · Screen every company in Pharmaceutical Preparations ↗